Used in the development of targeted cancer immunotherapies, particularly for hematological malignancies. Binds selectively to SLAMF6 (CD352), a receptor expressed on immune cells and certain tumor cells, enabling immune modulation or direct targeting of cancer cells. Investigated for its potential in antibody-drug conjugates (ADCs) to deliver cytotoxic agents specifically to tumor cells while sparing healthy tissue. Also serves as a tool in research to study immune cell signaling and tumor microenvironment interactions.